Back to results
US 9,040,479 B2Granted
HCV NS3 protease inhibitors
AssigneeCocrystal Pharma, Inc.
InventorSteven J. Coats
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds, compositions and methods for treating or preventing HCV viral infections in human patients or other animal hosts.
Claims8
A compound of Formula (I):
- or a pharmaceutically acceptable salt, or solvate thereof, wherein
- J and J1 can be present or absent, and when present are independently selected from the group consisting of lower alkyl (C1-C6), aryl, arylalkyl, alkoxy, aryloxy, heterocyclyl, heterocyclyloxy, keto, hydroxy, amino, arylamino, carboxyalkyl, carboxamidoalkyl, halo, cyano, formyl, sulfonyl, or sulfonamido;
- and
- R is alkyl (C1-C10), alkenyl (C2-C10), alkynyl (C2-C10), cycloalkyl(C3-C8), aryl, heteroaryl, or heterocyclyl each containing 1 to 9 fluorine atoms and/or 1 to 3 silicon atoms.
1 more element
Dependencies are inferred from the claim text.